simply crypto, Top

Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.AI glasses ushered in the limelight, and Google reached a cooperation with domestic manufacturers. According to the news, on December 13, at the Android XR conference, Google reached a strategic cooperation with domestic consumer-grade AR glasses manufacturer XREAL to jointly build the Android XR ecosystem. According to media reports, OPPO, vivo, Huawei, Tencent and ByteDance are all evaluating the AI glasses project. In addition, a number of listed companies said on the investor question and answer platform that they have corresponding technology or product reserves in AI glasses. Huaxin Securities Research Report pointed out that AI glasses have become a new outlet in the smart wear market, or lead the next generation of terminal revolution. AI glasses not only have the effect of virtual vision enhancement, but also realize real-time analysis of user behavior and environment by integrating artificial intelligence algorithms, providing more accurate and personalized services. AI glasses also improve comfort and prolong wearing time in design and portability. At the same time, it provides a more natural and convenient interactive experience innovation through various sensing technologies. With the gradual reduction of costs, AI glasses are expected to be further widely used. According to the report of Wellsenn XR, it is estimated that after 2030, the AI+AR smart glasses industry will enter a period of rapid development; By 2035, AI+AR smart glasses will eventually replace traditional smart glasses, and the global sales of AI+AR smart glasses will reach 1.4 billion units, which is equivalent to the size of smart phones and will become the next generation general computing platform and terminal. (Securities Times)The head of the region said that the Russian attack on the key infrastructure in the Ivano-Frankov region was the biggest attack on the region so far.

Japanese Prime Minister's Assistant: Japan must be prepared for Trump to impose tariffs. Japanese Prime Minister's Assistant Akihisa Nagashima said that Japan needs to be prepared for US President-elect Trump's threat to impose tariffs on China, Canada and Mexico, and adjust the supply chain to reduce the collateral damage suffered by Japanese enterprises. In an interview with the media on Thursday, Akihisa Nagashima said that he had "frank" communication with Trump team members on tariff issues during his recent visit to the United States. "I realized that Japan must be ready for Trump to implement his plan," he said. Akihisa Nagashima said that these tariff measures may encourage Japan to reduce its dependence on these three countries, where some Japanese companies operate and parts made in Japan are transported to these three countries to manufacture finished products for export to the United States. "Japanese companies will certainly try to restructure the supply chain," he pointed out. "This is economically reasonable." (Interface News)Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.